Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...